tirzepatide vs semaglutide efficacy weight loss of versus in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial | Diabetologia Semaglutide vs Tirzepatide for Weight

Peptides can interact with anaesthetic, anti-inflammatory, and blood thinning medications

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

These categories included genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication [2]

Competitive Pricing : Our competitive rates ensure top-notch care at a fraction of the cost compared to other clinics in Chandler, Portland, OR, and Vancouver, WA